title: Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
authors.affiliation: Mount Sinai School of Medicine, 311 East 79th Street, New York, NY 10021, USA.
authors.forename: Jay
authors.initials: J
authors.lastname: Desai
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Kolb
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Weitz
authors.forename: James
authors.initials: J
authors.lastname: Aisenberg
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy; D001562:Benzimidazoles / Q000009:adverse effects; D000069604:Dabigatran; D004724:Endoscopy / Q000009:adverse effects; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D009025:Morpholines / Q000009:adverse effects; D011720:Pyrazoles / Q000009:adverse effects; D011728:Pyridones / Q000009:adverse effects; D012307:Risk Factors; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control; D013876:Thiophenes / Q000009:adverse effects; D014859:Warfarin / Q000009:adverse effects; D015091:beta-Alanine / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran